Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

By afschroeder • July 27, 2025

Papp KA, Armstrong AW, Koresawa T, Otake K, Hirata M, Kano A. Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis. J Eur Acad Dermatol Venereol. 2025 Jul 25. doi: 10.1111/jdv.20863. Epub ahead of print. PMID: 40715001.

Tags: Dermatology, efficacy, ME3183, phosphodiesterase 4 inhibitor, plaque psoriasis, Publications, randomized controlled study, safety

Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease: A National Cohort Study of the MarketScan Databases

Cortes JA, Nong Y, Smart K, Aflatooni S, Palma G, Johnsen N, Ure A, Armstrong AW. Chronic Urticaria Is Independently Associated with Atherosclerotic Cardiovascular Disease:[...]

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis

Armstrong AW, Burne R, Bin Sawad A, Lemyre A, Gauthier-Loiselle M, Guerin A, Vinson T, Milovac B, Balu S. Treatment Patterns and Economic Burden in[...]

DNA methylation profiles at hospital admission are associated with subsequent severe COVID-19 outcomes

Hsu FM, Pickering H, Bosinger SE, Eckalbar W, Maecker HT, Kim-Schulze S, Ozonoff A, Diray-Arce J, Schaenman JM, Reed EF, Pellegrini M. DNA methylation profiles[...]